AZEK Coの空売り状況は、投資家がAZEK Coの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

AZEK Co (NYSE:AZEK) 株価情報, 空売り情報

AZEK Co

The AZEK Co Inc is a designer and manufacturer of beautiful, low maintenance and environmentally sustainable products focused on the fast-growing Outdoor Living market. Its portfolio of products includes decks, rail, trim, outdoor furniture among others. The company operates in two segments: Residential Segment that manufactures and distributes decking, railing, trim, moulding, pergolas and cabanas and accessories through a national network of dealers and distributors and multiple home improvement retailers; and Commercial Segment that manufactures, fabricates and distributes lockers and bathroom partitions. It generates maximum revenue from the Residential segment. The company's brand includes TimberTech; AZEK; Versatex, Ultralox, StruXure, and Intex.

The AZEK Company Inc. Class A Common Stock

The AZEK Co Inc

News

AMRK

A-Mark Precious Metals Acquires Stack's Bowers Galleries For $92M; Acquires AMS Holding For $50.0M; Acquires Pinehurst Coin Exchange For $6.5M

SenesTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>, ", SenesTech", or the ", Company", ))), a pioneer in fertility control solutions for managing rodent populations, announced today the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 374,718 shares of the Company's common stock originally issued by the Company on August 23, 2024, each having an original exercise price of $4.35 per share, at a reduced exercise price of $2.90 per share. In addition, the Company will issue new short-term warrants, as described below. The closing of the warrant exercise transaction is expected to occur on or about March 11, 2025, subject to Stockholder Approval (as defined herein) and satisfaction of customary closing conditions.
H.C. Wainwright is acting as the exclusive placement agent for the transaction.
The aggregate gross proceeds from the exercise of the existing warrants are expected to be approximately $1.1 million, before deducting placement agent fees and other offering expenses payable by the Company. The potential gross proceeds from the new short-term warrants, if fully exercised on a cash basis, will be approximately $4.3 million. No assurance can be given that any of the new short-term warrants will be exercised. The Company expects to use the net proceeds from the transaction for working capital and general corporate purposes.
The resale of the shares of common stock issuable upon the exercise of the existing warrants has been registered pursuant to an effective registration statement on Form S-3 (File No. 333-282286).

Offerings

SNES

SenesTech Announces Entry Into Definitive Agreements For The Immediate Exercise Of Certain Outstanding Warrants To Purchase An Aggregate Of 374,718 Shares Of Common Stock, Each Having An Original Exercise Price Of $4.35 Per Share, At A Reduced Exercise Price Of $2.90 Per Share For Gross Proceeds Of $1.1M

Management

Service Properties Trust Appoints Chris Bilotto As A Managing Trustee, President And Chief Executive Officer, Effective March 10, 2025

Strategy expects to make sales of perpetual strike preferred stock pursuant to the ATM Program in a disciplined manner over an extended period, taking into account the trading price and trading volumes of the perpetual strike preferred stock at the time of sale.
Strategy intends to use the net proceeds from the ATM Program for general corporate purposes, including the acquisition of bitcoin and for working capital.

MSTR

STRK

Strategy Announces $21B STRK At-The-Market Program

Biotech

General

HOTH

Hoth Therapeutics To Submit Expanded Access Application For HT-001

Stream Hatchet an influencer marketing company and live streaming analytics platform and wholly-owned subsidiary of GameSquare Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAME#NASDAQ">GAME</a>), ("GameSquare", or the "Company"), today announced a new contract with Capcom to support the launch of Monster Hunter Wilds. The contract is expected to contribute to GameSquare's revenue in 2025.
Under the terms of the contract, Stream Hatchet leveraged its best-in-class resources to help Capcom generate mass awareness for the release of the game, which has quickly become one of the most successful video game debuts of all time, breaking 1.3 million concurrent users on Steam, ranking 5th highest in Steam history and is Capcom's fastest selling game. Stream Hatchet's services include technology-enabled influencer discovery, talent sourcing, events production, and granular post-campaign performance analysis.
&nbsp;
"We are thrilled to be a part of one of the most successful video game launches of all time," stated Justin Kenna, GameSquare's CEO. "This contract with Capcom is a great example of the platform GameSquare and Stream Hatchet have created, highlighting our scale, technology, and best-in-class capabilities. Most importantly, it highlights Stream Hatchet's ability to leverage their leading technology and knowledge of gaming culture to produce successful outcomes for their customers."

Contracts

GAME

Stream Hatchet Enters Into A New Contract With Capcom To Support The Launch Of Monster Hunter Wilds

Preclinical Data Suggests Expanded Therapeutic Potential of the Hemopurifier&#xAE; Beyond Virology and Oncology
Results Support Further Evaluation of the Hemopurifier&#xAE;&nbsp;as Part of a Machine Perfusion Circuit to Further Assess its Impact on the Function of Retrieved Kidneys
SAN DIEGO, March 10, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4378620-1&amp;h=3653404512&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Faethlonmedical.com%2F___.YXAzOmFldGhsb246YTpvOmI3YWI2N2Q2OWRiZjI1MjAzMDg1MWYzYTRmNWQ4YjYxOjY6NjNiYTpmNzBkM2E2YjIwNTc2MDI1ZjRlZmJiMWVmMzQ5Mzg2MDJmMjk4M2EwZTcwOGM5NDUyOTJiNTY1NWFlNjFlYzhhOnA6VDpO&amp;a=Aethlon+Medical%2C+Inc.">Aethlon Medical, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases and for use in organ transplantation, today announced the publication of a pre-clinical study in&nbsp;the peer-reviewed journal Transplant Immunology (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4378620-1&amp;h=1949581366&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fdoi.org%2F10.1016%2Fj.trim.2025.102215___.YXAzOmFldGhsb246YTpvOjdmZGM3ZDI2M2E4NTU5MWQxY2Q4MmFkODkzNDUwYzZjOjY6NmNjYTo1OGI0ZWE0NTFhZDY1NGY0OGQ5ZWRjZGM5NmZlYWVkNjNhMzAzZmM5ZGQzZTZiZmNlMjIyYWM5NGI1NjdhODFkOnA6VDpO&amp;a=https%3A%2F%2Fdoi.org%2F10.1016%2Fj.trim.2025.102215">https://doi.org/10.1016/j.trim.2025.102215</a>) on February 28, 2025, entitled, " A lectin affinity plasmapheresis device removes extracellular vesicles and microRNAs from renal perfusates following controlled oxygenated rewarming of discarded donor kidneys."
Aethlon Medical's Hemopurifier&#xAE;&nbsp;is a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles and life-threatening viruses from blood and other biological fluids. Its capabilities have potential applications in oncology and infectious diseases, and organ transplantation.

AEMD

Aethlon Medical Publishes Preclinical Data On The Hemopurifier In Transplant Immunology Journal Entitled, " A Lectin Affinity Plasmapheresis Device Removes Extracellular Vesicles And MicroRNAs From Renal Perfusates Following Controlled Oxygenated Rewarming Of Discarded Donor Kidneys."

NET Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPWR#NYSE">NPWR</a>) reported quarterly losses of $(0.46) per share. This is a 235.29 percent decrease over earnings of $0.34 per share from the same period last year.

Earnings

NPWR

NET Power Q4 2024 GAAP EPS $(0.46) Down From $0.34 YoY

– Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair –
– Publication of the Budget Impact Model in peer-reviewed journal supports Symvess as a treatment that provides economic value to hospitals and payers –
DURHAM, N.C., March 10, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>), a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the publication of the Budget Impact Model for Symvess in the Journal of Medical Economics. The publication, titled "Budget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible," reported that Symvess was projected to be cost saving for both trauma centers and third-party payers, primarily due to reductions in the costs related to amputations and conduit infections.

HUMA

Humacyte Announces Symvess Cost-Saving Benefits In Journal Of Medical Economics; Supports Economic Value For Hospitals And Payers

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>Dividend Yield: 4.01%</li>
<li>Truist Securities analyst David Macdonald maintained a Buy rating and raised the price target from $60 to $76 on Feb. 13, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Leerink Partners analyst Michael Cherny upgraded the stock from Market Perform to Outperform and boosted the price target from $55 to $75 on Feb. 13, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On March 4, Wellvana and CVS Health disclosed that Wellvana has acquired the Medicare Shared Savings Program business of CVS Accountable Care&#x2122;, part of CVS Health, in an all-stock transaction.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1">CVS news</a>. </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/59c9cf91-f220-445e-9cc8-fb8e60e12227" alt="" style="width:620px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.06%</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $60 to $62 on Feb. 7, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and boosted the price target from $60 to $65 on Jan. 28, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On March 7, the European Commission (EC) approved Bristol Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC), a type of liver cancer.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1">BMY news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="910" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221826/image-43.png" alt="" class="wp-image-815700" style="width:563px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221826/image-43.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221826/image-43-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221826/image-43-768x701.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<h3 class="wp-block-heading">Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</h3>
<ul>
<li>Dividend Yield: 2.98%</li>
<li>Guggenheim analyst Vamil Divan maintained a Neutral rating and raised the price target from $162 to $166 on Feb. 3, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Barclays analyst Matt Miksic maintained an Equal-Weight rating and increased the price target from $159 to $166 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On March 7, Johnson &amp; Johnson decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment for major depressive disorder (aMDD).</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1">latest JNJ news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent031025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="905" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221911/image-44.png" alt="" class="wp-image-815702" style="width:570px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221911/image-44.png 905w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221911/image-44-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/09221911/image-44-768x702.png 768w" sizes="(max-width: 905px) 100vw, 905px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

GDOT

Green Dot Announces Review of Strategic Alternatives; Co. Also Appoints William I Jacobs As Interim CEO

NV5 Global, Inc. (the "Company" or "NV5") (NASDAQ:<a href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>), a provider of technology, certification, and consulting solutions, announced today that it has been awarded $18 million in recent data center design and commissioning contracts throughout the U.S. and Asia, reinforcing its position as a leader in the rapidly expanding data center sector. These new agreements amplify NV5's role in developing and optimizing infrastructure to meet the growing demands for cloud computing and AI-driven operations.
NV5 will implement high-efficiency cooling and power distribution testing, inspection, certification and design solutions for both new and retrofitted facilities. With the growing strain on electrical infrastructure from AI workloads, NV5's proven expertise in sustainable design and operational resilience has become a valued resource for clients seeking innovative solutions to scale their data center capabilities.

NVEE

NV5 Global Has Been Awarded $18M In Recent Data Center Design And Commissioning Contracts Throughout The U.S. And Asia

New data showed that a single dose of a tumor-selective triple knockout ("3KO") RT virus with a specific immunotherapeutic payload (undisclosed) has dramatically altered the tumor microenvironment, characterized by marked increases in CD45+ leukocytes, CD3+ and CD8+ T cells. Specifically, the leukocyte infiltration reached 80% for 3KO RT and 92% for the 3KO RT with the payload, compared to 46% for the untreated arm. These new data confirm the production of immunomodulated payload specifically at the tumor sites. These significant shifts in immune composition, driven by 3KO RT with payload, ultimately led to complete eradication of certain tumors in the preclinical model.

CLDI

Calidi Biotherapeutics Highlights Delivery Of Transient Gene Therapy (Payload) To Tumors Using Systemic Platform

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.becn.com%2F&amp;esheet=54221248&amp;newsitemid=20250310934468&amp;lan=en-US&amp;anchor=Beacon&amp;index=1&amp;md5=5a8b2212562735e5fa58f90845210a9a">Beacon</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BECN#NASDAQ">BECN</a>), the leading publicly-traded specialty wholesale distributor of roofing, waterproofing and related exterior products, announced today a strategic investment and partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.renovaterobotics.com%2F&amp;esheet=54221248&amp;newsitemid=20250310934468&amp;lan=en-US&amp;anchor=Renovate+Robotics&amp;index=2&amp;md5=73c6a2b93490e4dee8cf628482d88b4b">Renovate Robotics</a> - a pioneer in roofing automation.
Renovate Robotics, based in Brooklyn, New York, is the leading startup developing autonomous roofing robots with a focus on making roofing safer and more productive for contractors. Their first robot, Rufus, installs asphalt shingles on residential roofs and is expected to launch with contractors in New Jersey and Pennsylvania later this year.

BECN

Beacon Announced Strategic Investment In Renovate Robotics For Roofing Automation; Terms Not Disclosed

BYON

Beyond Board Appoints Executive Chairman Marcus Lemonis As Principal Executive Officer And Adrianne Lee As President & CEO

HC Wainwright &amp; Co. analyst Oren Livnat maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and raises the price target from $200 to $217.

JAZZ

HC Wainwright & Co. Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $217

Concentra&#xAE;, the nation's leader in occupational medicine, today announced the acquisition of the assets of Physicians Health Center (PHC) and OM Management (OMM).
<ul>
<li>The PHC Airport location at 6221 NW 36th Street, Virginia Gardens, Florida 33166 will become Concentra Miami Airport.</li>
<li>The PHC Hialeah location at 6990 NW 37th Avenue, Miami, Florida 33147 will become Concentra Hialeah East.</li>
<li>The PHC South Dade location at 1448 North Krome Avenue, Suite 101, Florida City, Florida 33034 will become Concentra Florida City.</li>
<li>The PHC Kendall location at 7887 North Kendall Drive, Suite 102, Miami, Florida 33156 will become Concentra South Miami.</li>
<li>The PHC North Dade location at 20535 NW 2nd Avenue, Suite 150, Miami, Florida 33169 will become Concentra Miami Gardens.</li>
<li>The OM Management corporate office location will become a satellite office for Concentra's CMCA group.</li>
</ul>

Concentra Acquires Physicians Health Center And OM Management; No Financial Terms Disclosed

Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) reported quarterly losses of $(13.08) per share which missed the analyst consensus estimate of $(2.30) by 468.7 percent. This is a 137.82 percent decrease over losses of $(5.50) per share from the same period last year. The company reported quarterly sales of $629.00 thousand which beat the analyst consensus estimate of $433.33 thousand by 45.15 percent. This is a 68.69 percent decrease over sales of $2.01 million the same period last year.

Earnings Beats

Earnings Misses

ALGS

Aligos Therapeutics Q4 EPS $(13.08) Misses $(2.30) Estimate, Sales $629.00K Beat $433.33K Estimate

Median follow-up time at 18 months was 18.7 months after the three-month CR.&nbsp;

Health Care

URGN

UroGen Reported Updated 18-month Duration Of Response Data From The Phase 3 Envision Trial Of UGN-102 For Low-grade Intermediate Risk Non-muscle Invasive Bladder Cancer, With A DOR Rate Of 80.6% At 18-months Compared To 82.5% At 12-months

The World Health Organization (WHO) recently reaffirmed the spread of new clade Ib Mpox a public health emergency of international concern (PHEIC): second Mpox-related WHO PHEIC declaration in two years
Clade Ib Mpox cases detected in several countries in Central and Eastern Africa as well as China, Thailand, Singapore, India, England, parts of Europe and the Middle East, Canada and the United States
Tolerability of TNX‐801 vaccination in immune-compromised animal models supports clinical development
CHATHAM, N.J., March 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced it has been awarded a grant from the Medical CBRN Defense Consortium (MCDC) to support the development of TNX-801 (recombinant horsepox virus, live vaccine). MCDC is a consortium of industrial, academic, and non-profit entities that supports the U.S. government in meeting military requirements for medical products to protect against chemical, biological, radiological and nuclear (CBRN) threats. TNX-801 is in development as an mpox and smallpox vaccine with the potential to be delivered via innovative alternative methods to improve patient compliance, ease of use and tolerability. The MCDC grant will allow for further comprehensive market analyses, target market identification and commercialization planning, including for both private and government markets.
"We are excited by the opportunity to collaborate with MCDC and are thankful for their support of our vaccine candidate," said Seth Lederman, M.D., President, and Chief Executive Officer of Tonix. "TNX-801 offers an appealing target product profile, requiring just a single dose for durable, long-term protection, with favorable shipping and storage requirements. With a significant global unmet need, TNX-801 is in a strong position to make a potential impact towards preventing mpox and controlling mpox epidemics."

TNXP

Tonix Pharmaceuticals Receives Grant By Medical CBRN Defense Consortium For Development Of TNX-801, Company's Single-Dose Mpox And Smallpox Vaccine Candidate

Comments

AZEK Co

空売り

AZEK Co (NYSE:AZEK) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル